X4 Pharmaceuticals (XFOR) Competitors $3.38 -0.19 (-5.32%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$3.38 0.00 (-0.15%) As of 09/25/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XFOR vs. ELDN, BHST, CYBN, LFVN, AVTX, NKTX, MCRB, ACTU, CRDF, and SKYEShould you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Eledon Pharmaceuticals (ELDN), BioHarvest Sciences (BHST), Cybin (CYBN), Lifevantage (LFVN), Avalo Therapeutics (AVTX), Nkarta (NKTX), Seres Therapeutics (MCRB), Actuate Therapeutics (ACTU), Cardiff Oncology (CRDF), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry. X4 Pharmaceuticals vs. Its Competitors Eledon Pharmaceuticals BioHarvest Sciences Cybin Lifevantage Avalo Therapeutics Nkarta Seres Therapeutics Actuate Therapeutics Cardiff Oncology Skye Bioscience X4 Pharmaceuticals (NASDAQ:XFOR) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Do analysts prefer XFOR or ELDN? X4 Pharmaceuticals presently has a consensus target price of $34.17, indicating a potential upside of 910.85%. Eledon Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 304.86%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe X4 Pharmaceuticals is more favorable than Eledon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Eledon Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is XFOR or ELDN more profitable? Eledon Pharmaceuticals has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -311.15%. Eledon Pharmaceuticals' return on equity of -92.51% beat X4 Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets X4 Pharmaceuticals-311.15% -375.31% -72.87% Eledon Pharmaceuticals N/A -92.51%-38.31% Do institutionals & insiders believe in XFOR or ELDN? 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 2.4% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, XFOR or ELDN? Eledon Pharmaceuticals has lower revenue, but higher earnings than X4 Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioX4 Pharmaceuticals$2.56M15.06-$37.45M-$14.84-0.23Eledon PharmaceuticalsN/AN/A-$36.18M-$1.17-2.11 Does the media prefer XFOR or ELDN? In the previous week, Eledon Pharmaceuticals had 5 more articles in the media than X4 Pharmaceuticals. MarketBeat recorded 6 mentions for Eledon Pharmaceuticals and 1 mentions for X4 Pharmaceuticals. X4 Pharmaceuticals' average media sentiment score of 1.89 beat Eledon Pharmaceuticals' score of 1.26 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment X4 Pharmaceuticals Very Positive Eledon Pharmaceuticals Positive Which has more risk and volatility, XFOR or ELDN? X4 Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. SummaryX4 Pharmaceuticals and Eledon Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XFOR vs. The Competition Export to ExcelMetricX4 PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.73M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-0.2320.6375.7726.11Price / Sales15.06442.69544.74124.93Price / CashN/A44.6737.5461.24Price / Book0.879.6212.876.30Net Income-$37.45M-$52.73M$3.29B$271.03M7 Day Performance4.32%0.64%-0.26%-0.15%1 Month Performance-14.86%6.31%3.84%6.41%1 Year Performance-82.48%18.97%68.35%28.81% X4 Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XFORX4 Pharmaceuticals4.6091 of 5 stars$3.38-5.3%$34.17+910.8%-82.5%$40.73M$2.56M-0.2380Positive NewsELDNEledon Pharmaceuticals2.9331 of 5 stars$2.46+1.7%$10.00+306.5%-0.8%$144.91MN/A-2.1010News CoveragePositive NewsBHSTBioHarvest Sciences2.2124 of 5 stars$9.08+3.1%$13.67+50.5%N/A$144.71M$25.19M-12.97N/AGap UpHigh Trading VolumeCYBNCybin2.7046 of 5 stars$6.01-1.3%$85.00+1,314.3%N/A$141.78MN/A-1.3750LFVNLifevantage3.9615 of 5 stars$10.68-4.0%$30.50+185.6%-15.7%$141.25M$228.53M14.43260AVTXAvalo Therapeutics3.9336 of 5 stars$10.14-4.8%$30.00+195.9%+27.3%$140.14M$440K0.0040Positive NewsNKTXNkarta2.1333 of 5 stars$1.97flat$13.60+590.4%-57.4%$139.92MN/A-1.33140Positive NewsMCRBSeres Therapeutics1.7468 of 5 stars$15.69-1.4%$73.67+369.5%+3.2%$139.29M$126.32M-3.41330Analyst ForecastACTUActuate Therapeutics2.3901 of 5 stars$7.00+4.9%$20.33+190.5%+14.7%$138.60MN/A0.0010Trending NewsAnalyst ForecastAnalyst RevisionCRDFCardiff Oncology2.3115 of 5 stars$2.04-0.5%$10.63+420.8%-23.9%$136.38M$680K-2.3420Positive NewsSKYESkye Bioscience1.8162 of 5 stars$4.07-4.2%$15.50+280.8%-7.5%$131.70MN/A-3.8411High Trading Volume Related Companies and Tools Related Companies ELDN Competitors BHST Competitors CYBN Competitors LFVN Competitors AVTX Competitors NKTX Competitors MCRB Competitors ACTU Competitors CRDF Competitors SKYE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XFOR) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredChina Targets MAGA In Stealth Trade War TacticsChina is deliberately targeting the economic backbone of conservative America - The very industries that supp...Goldco Precious Metals | SponsoredCollege grad makes $64,000 a monthNothing hurts like a missed opportunity... And with AI stocks like Nvidia, Palantir, and Oracle continuing...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XFOR Stock Alerts